8 ms·
> I'm glad these tools exist and do help people, though I do think the potential risks are downplayed in our society. I have been dealing with severe akathisia
by disabled 4y ago
> I'm glad these tools exist and do help people, though I do think the potential risks are downplayed in our society.
I have been dealing with severe akathisia from medications I took for severe depression.
I have 2 rare immune mediated neurological diseases affecting my peripheral nervous system plus type 1 diabetes. None of this is even remotely as bad as the akathisia.
There are people who are cancer survivors, combat veterans, rape survivors, who all say that akathisia by far takes the cake in terms of traumatic experiences.
Please if you are going to be taking psych meds of any type, get genetic testing done:
https://Genomind.com https://Genomind.com
It is covered 100% by original Medicare and/or Medicaid. So, it is not like it is some non-proven technology.
You can develop akathisia spontaneously, too, so even if you are on psych meds now, you need to get tested.
- SpodGaju 4y agoSorry man, I know several people who were injured by some of these meds. It is not talked about enough when they prescribe them. Regarding Genomind, these are really limited in how much they will help. They test a limited amount of genes that "might" change drug efficacy. Even taking into account the CYP genetics, if someone is anemic these enzymes will function more slowly so emvironment will trump genetics. https://jamanetwork.com/journals/jama/article-abstract/195392 https://jamanetwork.com/journals/jama/article-abstract/19539... "At this time, DTC advertisements are inappropriate, given the public's limited sophistication regarding genetics and the lack of comprehensive premarket review of tests or oversight of advertisement content." And from the really the only study claiming that Genomind is effective, from their website: https://genomind.com/the-science/ https://genomind.com/the-science/ Citation: Perlis RH, et al. Pharmacogenetic testing among patients with mood and anxiety disorders is associated with decreased utilization and cost: A propensity-score matched study. Depression & Anxiety. 2018;35(10):946-952. doi:10.1002/da.22742 "Dr. Imbens reports personal fees from Genomind, for experimental design related to the submitted work, and personal fees from Eli Lilly, outside the submitted work." And if you look through all of those studies you will find they were funded by Genomind.